Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement.
The present work investigates the effect of liquid lipid incorporation on the physicochemical properties and ocular drug delivery enhancement of nanostructured lipid carriers (NLCs) and attempts to elucidate in vitro and in vivo the potential of NLCs for ocular drug delivery. The CyA-loaded or fluorescein-marked nanocarriers composed of Precifac ATO 5 and Miglyol 840 (as liquid lipid) were prepared by melting-emulsion technology, and the physicochemical properties of nanocarriers were determined. The uptake of nanocarriers by human corneal epithelia cell lines (SDHCEC) and rabbit cornea was examined. Ex vivo fluorescence imaging was used to investigate the ocular distribution of nanocarriers. The in vitro cytotoxicity and in vivo acute tolerance were evaluated. The higher drug loading capacity and improved in vitro sustained drug release behavior of lipid nanoparticles was found with the incorporation of liquid lipid in lipid nanoparticles. The uptake of nanocarriers by the SDHCEC was increased with the increase in liquid lipid loading. The ex vivo fluorescence imaging of the ocular tissues indicated that the liquid lipid incorporation could improve the ocular retention and penetration of ocular therapeutics. No alternation was macroscopically observed in vivo after ocular surface exposure to nanocarriers. These results indicated that NLC was a biocompatible and potential nanocarrier for ocular drug delivery enhancement.
Shen
Jie
J
School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.
Sun
Minjie
M
Ping
Qineng
Q
Ying
Zhi
Z
Liu
Wen
W
D000818:Animals; D002460:Cell Line; D004337:Drug Carriers / Q000138:chemical synthesis / Q000493:pharmacokinetics* / Q000633:toxicity*; D019573:Epithelium, Corneal / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D006801:Humans; D008055:Lipids / Q000737:chemistry / Q000493:pharmacokinetics* / Q000633:toxicity*; D008422:Materials Testing; D008657:Metabolic Clearance Rate; D050997:Nanomedicine / Q000379:methods; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D011817:Rabbits; D012996:Solutions
D004337:Drug Carriers; D008055:Lipids; D012996:Solutions